Controversial CRISPR paper earns second editorial note – Retraction Watch (blog)
High Point Observer |
Controversial CRISPR paper earns second editorial note
Retraction Watch (blog) When “Unexpected mutations after CRISPR–Cas9 editing in vivo” was published May 30, it immediately drew criticism from many of the top scientists working with CRISPR, including those associated with companies seeking to develop CRISPR-based … $-0.42 EPS Expected for Intellia Therapeutics (NTLA), Colony Financial (CLNY) Sentiment Is 0.92 The Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of “Buy” by Analysts |
